Development and internal validation of a clinical and genetic risk score for rheumatoid arthritis-associated interstitial lung disease
Authors' conclusion
A clinical and genetic risk model discriminated ILD in a large, multicentre RA cohort better than a clinical-only model, excluding 20% of the cohort from low-yield testing.
Study context
- Population
- Participants in the Veterans Affairs RA (VARA) registry genotyped for 12 single nucleotide polymorphisms (SNPs) associated with idiopathic pulmonary fibrosis (89% male, mean age 69.5 years)9.4% had ILD
- Participants
- 2,386 participants
- Comparison
- Combined clinical and genetic risk model vs clinical-only model
- Outcome
- Discrimination of ILD (AUC)
Methodological detailsmulticentre, prospective cohort, logistic regression, bootstrapping internal validation
- Multicentre
- Prospective cohort
- Logistic regression
- Bootstrapping internal validation
Performance
As reported in the abstract
Discrimination of ILD, AUC
| Test or model | AUC | Shrinkage-corrected AUC (95% CI 0.628, 0.712) | Shrinkage-corrected AUC (95% CI 0.584, 0.651) |
|---|---|---|---|
| Combined | 0.675 | 0.667 | — not stated in the abstract |
| Clinical-only | 0.635 | — not stated in the abstract | 0.623 |
AUC
Combined0.675
Clinical-only0.635
Shrinkage-corrected AUC (95% CI 0.628, 0.712)
Combined0.667
Clinical-only— not stated in the abstract
Shrinkage-corrected AUC (95% CI 0.584, 0.651)
Combined— not stated in the abstract
Clinical-only0.623
— not stated in the abstract
- Combined vs Clinical-only: P < 0.001
Further findings
- Cohort with combined risk score below a cut-point with >90% sensitivity
- Twenty percent
Original publication
Development and internal validation of a clinical and genetic risk score for rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford). Published 18 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →